Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

The antihypertensive actions of glucagon-like peptide-1 (GLP1) receptor agonists have been linked to the release of atrial natriuretic peptide (ANP) in mice. Whether a GLP1-ANP axis exists in humans is unknown. In this study, we examined 12 healthy young males in a randomized, controlled, double-blinded, single-day, cross-over study to evaluate the effects of a 2-h native GLP1 infusion. Plasma ...

Evaluation of Serum Levels of N-terminal Pro Brain Natriuretic Peptide and Atrial Natriuretic Peptide in Neonates with Respiratory Distress

Background: Acute respiratory distress (ARD) is a critical respiratory failure due to lung injury of neonates leading to the clinical appearance of poor lung compliance. The aimed of the study was to evaluate the diagnostic values in differentiating respiratory from heart diseases with using of N-terminal pro brain natriuretic peptide (NT-pro BNP) and Atrial natriuretic peptide(ANP) in neonates...

Glucagon-like peptide-1 receptor-atrial natriuretic peptide axis: a novel mechanism for blood pressure regulation.

evaluation of serum levels of n-terminal pro brain natriuretic peptide and atrial natriuretic peptide in neonates with respiratory distress

background: acute respiratory distress (ard) is a critical respiratory failure due to lung injury of neonates leading to the clinical appearance of poor lung compliance. the aimed of the study was to evaluate the diagnostic values in differentiating respiratory from heart diseases with using of n-terminal pro brain natriuretic peptide (nt-pro bnp) and atrial natriuretic peptide(anp) in neonates...

Glucagon-Like Peptide-1

Ma Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury. It can reduce infarct size, ischemic left ventricular dysfunction, and myocardial stunning. GLP-1 receptor agonists have also been shown to reduce ...